A quick peek into the report
Table of Contents
1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
1.3 Key Market Trends
1.3.1 Impact Analysis
1.4 Regulatory Landscape
1.5 Pipeline Analysis
1.6 Market Dynamics
1.6.1 Overview
1.6.2 Market Drivers
1.6.3 Market Restraints
1.6.4 Market Opportunities
2.1 Intravenous
2.2 Oral
2.3 Topical
3.1 North America
3.1.1 Market Dynamics
3.1.2 Market Sizing and Forecast
3.1.3 North America Herpes Zoster Market, by Country ($Million), 2023-2035
3.1.3.1 U.S.
3.1.3.2 Canada
3.2 Europe
3.2.1 Market Dynamics
3.2.2 Market Sizing and Forecast
3.2.3 Europe Herpes Zoster Market, by Country ($Million), 2023-2035
3.2.3.1 U.K.
3.2.3.2 France
3.2.3.3 Germany
3.2.3.4 Italy
3.2.3.5 Spain
3.2.3.6 Rest-of-Europe
3.3 Asia-Pacific
3.3.1 Market Dynamics
3.3.2 Market Sizing and Forecast
3.3.3 Asia-Pacific Herpes Zoster Market, by Country ($Million), 2023-2035
3.3.3.1 Japan
3.3.3.2 China
3.3.3.3 India
3.3.3.4 Australia
3.3.3.5 South Korea
3.3.3.6 Rest-of-Asia-Pacific
3.4 Rest-of-the-World
3.4.1 Market Dynamics
3.4.2 Market Sizing and Forecast
3.4.3 Rest-of-the-World Herpes Zoster Market, by Country ($Million), 2023-2035
3.4.3.1 Latin America
3.4.3.2 Middle East and Africa
4.1 Competitive Landscape
4.1.1 Mergers and Acquisitions
4.1.2 Partnership, Alliances and Business Expansion
4.1.3 New Offerings
4.1.4 Regulatory Activities
4.1.5 Funding Activities
4.2 Company Profiles
4.2.1 Abbott Laboratories
4.2.1.1 Overview
4.2.1.2 Top Products / Product Portfolio
4.2.1.3 Top Competitors
4.2.1.4 Target Customers/End-Users
4.2.1.5 Key Personnel
4.2.1.6 Analyst View
4.2.2 Astellas Pharma Inc.
4.2.2.1 Overview
4.2.2.2 Top Products / Product Portfolio
4.2.2.3 Top Competitors
4.2.2.4 Target Customers/End-Users
4.2.2.5 Key Personnel
4.2.2.6 Analyst View
4.2.3 Cipla
4.2.3.1 Overview
4.2.3.2 Top Products / Product Portfolio
4.2.3.3 Top Competitors
4.2.3.4 Target Customers/End-Users
4.2.3.5 Key Personnel
4.2.3.6 Analyst View
4.2.4 Eli Lilly and Company
4.2.4.1 Overview
4.2.4.2 Top Products / Product Portfolio
4.2.4.3 Top Competitors
4.2.4.4 Target Customers/End-Users
4.2.4.5 Key Personnel
4.2.4.6 Analyst View
4.2.5 GSK plc
4.2.5.1 Overview
4.2.5.2 Top Products / Product Portfolio
4.2.5.3 Top Competitors
4.2.5.4 Target Customers/End-Users
4.2.5.5 Key Personnel
4.2.5.6 Analyst View
4.2.6 Hoffmann-La Roche Ltd
4.2.6.1 Overview
4.2.6.2 Top Products / Product Portfolio
4.2.6.3 Top Competitors
4.2.6.4 Target Customers/End-Users
4.2.6.5 Key Personnel
4.2.6.6 Analyst View
4.2.7 Merck & Co., Inc.
4.2.7.1 Overview
4.2.7.2 Top Products / Product Portfolio
4.2.7.3 Top Competitors
4.2.7.4 Target Customers/End-Users
4.2.7.5 Key Personnel
4.2.7.6 Analyst View
4.2.8 Novartis AG
4.2.8.1 Overview
4.2.8.2 Top Products / Product Portfolio
4.2.8.3 Top Competitors
4.2.8.4 Target Customers/End-Users
4.2.8.5 Key Personnel
4.2.8.6 Analyst View
4.2.9 Pfizer Inc
4.2.9.1 Overview
4.2.9.2 Top Products / Product Portfolio
4.2.9.3 Top Competitors
4.2.9.4 Target Customers/End-Users
4.2.9.5 Key Personnel
4.2.9.6 Analyst View
4.2.10 Teva Pharmaceutical Industries Ltd
4.2.10.1 Overview
4.2.10.2 Top Products / Product Portfolio
4.2.10.3 Top Competitors
4.2.10.4 Target Customers/End-Users
4.2.10.5 Key Personnel
4.2.10.6 Analyst View
4.2.11 Others
Research Methodology
Table: Global Herpes Zoster Market (by Route of Administration), $Million, 2023-2035
Table: Global Herpes Zoster Market (by Region), $Million, 2023-2035
Figure: Global Herpes Zoster Market Coverage
Figure: Global Herpes Zoster Market Key Trends, Impact Analysis, 2023-2035
Herpes Zoster Market Report Coverage
|
Herpes Zoster Market |
|||
|
Base Year |
2024 |
Market Size in 2024 |
$XX Billion |
|
Forecast Period |
2025-2035 |
Value Projection and Estimation by 2035 |
$XX Billion |
|
CAGR During Forecast Period |
XX% |
|
|
Some of the prominent names established in this market are:
• Abbott Laboratories
• Astellas Pharma Inc.
• Cipla
• Eli Lilly and Company
• GSK plc
• Hoffmann-La Roche Ltd
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc
• Teva Pharmaceutical Industries Ltd
How can this report add value to an organization?
Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in herpes zoster, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.
Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.
Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors’ strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.
Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.
Global Herpes Zoster Market, Analysis and Forecast: 2025-2035
Herpes Zoster, also known as shingles, is a viral infection caused by the reactivation of the varicella-zoster virus, which also causes chickenpox. The condition is characterized by a painful, blistering rash that typically affects one side of the body, often around the torso or face. Herpes zoster primarily occurs in individuals who have had chickenpox earlier in life, with the virus remaining dormant in nerve cells and reactivating later in life, usually when the immune system is weakened. Risk factors include older age, immunocompromised states (such as HIV/AIDS, cancer treatments, or organ transplantation), and stress. The diagnosis of herpes zoster is generally based on clinical symptoms, with laboratory tests used in atypical cases.
Treatment for herpes zoster includes antiviral medications such as acyclovir, valacyclovir, and famciclovir, which can reduce the severity and duration of the infection if administered early. Additionally, pain management is a critical component, with options including analgesics, anticonvulsants, and nerve blocks. The market for herpes zoster treatments is expanding, driven by factors such as the increasing global aging population, growing awareness about the importance of early treatment, and the availability of vaccines to prevent shingles.
The herpes zoster market is primarily driven by the rising prevalence of the condition in older populations, where the immune system naturally weakens with age, increasing the likelihood of viral reactivation. The approval and availability of vaccines, such as Shingrix, have significantly boosted prevention efforts and reduced the burden of the disease. Moreover, the growing awareness among both healthcare professionals and the general public regarding the potential severity of herpes zoster, including the risk of postherpetic neuralgia (PHN), a debilitating complication of shingles, has led to more proactive management and treatment of the condition.
Recent advancements in herpes zoster treatment have focused on improving the effectiveness of antiviral medications and pain management strategies, including the development of combination therapies that target both the virus and its associated pain. Additionally, research into the long-term effects of vaccination and the development of more efficient, long-lasting vaccines continues to shape the market. The growing focus on personalized treatments, especially for those with compromised immune systems, is also driving market growth.
Despite this growth, the herpes zoster market faces challenges, such as the underdiagnosis and underreporting of shingles, particularly in younger populations who may not recognize the symptoms early enough for effective antiviral treatment. Additionally, vaccine access remains an issue in some regions, especially in low- and middle-income countries, limiting preventative care options. The high cost of new vaccines and the potential for side effects in certain patient populations also represent barriers to widespread adoption.
The competitive landscape of the herpes zoster market is evolving, with major pharmaceutical companies, including Merck & Co., Inc., Novartis AG, and Pfizer Inc., leading the way with vaccine development and antiviral therapies. Emerging companies are focusing on improving treatment regimens, addressing vaccine accessibility, and exploring new pain management solutions. Collaborative efforts between healthcare providers, research institutions, and pharmaceutical companies continue to drive innovation, with a shared goal of reducing the incidence and burden of herpes zoster through better prevention and treatment options.
Market Segmentation:
Segmentation 1: by Route of Administration
• Intravenous
• Oral
• Topical
Segmentation 2: by Region
• North America
• Europe
• Asia-Pacific
• Rest-of-the-World
The global herpes zoster market is growing due to several key factors, including the rising prevalence of the condition, particularly in aging and immunocompromised populations, which has increased demand for effective treatments and prevention. Advances in vaccine development, such as the approval of Shingrix, have significantly improved prevention, while the introduction of better antiviral therapies and pain management options has expanded treatment choices. Increased awareness of herpes zoster and its complications, particularly postherpetic neuralgia, has led to earlier diagnoses and higher vaccine uptake. Furthermore, greater healthcare access and rising investments in research are driving the development of more effective vaccines and treatments, contributing to the market's growth.
Herpes Zoster Market - A Global and Regional Analysis
Focus on Route of Administration and Region - Analysis and Forecast, 2025-2035
This report will be delivered in 7-10 working days.
Frequently Asked Questions
The global herpes zoster market is led by prominent pharmaceutical companies such as Amgen Inc, Arrowhead Pharmaceuticals, Inc., AstraZeneca, Eli Lilly and Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc. and Sanofi.
Trends:
• Shift towards recombinant vaccines
• Integration of mRNA vaccine technology
• Expansion in emerging markets
• Focus on personalized medicine
Driver:
• Aging global population
• Rising awareness and vaccination uptake
• Advancements in therapeutic options
• Increased healthcare expenditure
• High treatment costs
• Limited vaccine accessibility
• Underdiagnosis and misdiagnosis
• Side effects of treatments
• Advancements in vaccine technology
• Increasing awareness and education
• Expanding healthcare access in emerging markets
• Integration of digital health solutions
• Research into broader health benefits of vaccination